Table 2.
Sites of relapse with the corresponding treatment for the analyzed cohort
| Site of relapse | Recurrence treatment | Total | |||
|---|---|---|---|---|---|
| Chemotherapy | Surgery | CRS + / − HIPEC | Best supportive care | ||
| Peritoneal | 18 | 0 | 7 | 12 | 37 |
| 31.0% | 0.0% | 12.1% | 20.7% | 63.8% | |
| Visceral | 3 | 2 | 0 | 0 | 5 |
| 5.2% | 3.4% | 0.0% | 0.0% | 8.6% | |
| Locoregional | 8 | 7 | 0 | 1 | 16 |
| 13.8% | 12.1% | 0.0% | 1.7% | 27.6% | |
| Total | 29 | 9 | 7 | 13 | 58 |
| 50.0% | 15.5% | 12.1% | 22.4% | 100.0% | |
CRS cytoreductive surgery, HIPEC hyperthermic intra-peritoneal chemotherapy